Overview

Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases

Status:
RECRUITING
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
The goal of this study is to evaluate the safety and effi cacy of CD19 CAR T cells in the treatment of Refractory Autoimmune Diseases.
Phase:
PHASE1
Details
Lead Sponsor:
Beijing GoBroad Hospital